{"id":"cardiovascular-polypill","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Bleeding risk"}]},"_chembl":{"chemblId":"CHEMBL6995","moleculeType":"Small molecule","molecularWeight":"266.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The polypill integrates several established cardiovascular drugs into a single tablet to improve medication adherence and provide synergistic cardioprotection. By combining agents that work through different pathways—such as antihypertensives, statins, and antiplatelet drugs—it aims to reduce overall cardiovascular event risk more effectively than individual medications while simplifying the treatment regimen.","oneSentence":"A fixed-dose combination pill that combines multiple cardiovascular agents to reduce the risk of heart disease and stroke through complementary mechanisms including blood pressure lowering, lipid reduction, and antiplatelet effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:02.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular disease prevention and secondary prevention in high-risk patients"}]},"trialDetails":[{"nctId":"NCT06930885","phase":"PHASE3","title":"Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2025-06-12","conditions":"Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)","enrollment":7713},{"nctId":"NCT02596126","phase":"PHASE3","title":"Secondary Prevention of Cardiovascular Disease in the Elderly Trial","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2016-07","conditions":"Myocardial Infarction, Cardiovascular Disease","enrollment":2499},{"nctId":"NCT01326676","phase":"PHASE3","title":"Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2011-02","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT01313702","phase":"PHASE3","title":"Single Pill to Avert Cardiovascular Events","status":"WITHDRAWN","sponsor":"Hospital do Coracao","startDate":"2012-10","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT03459560","phase":"PHASE3","title":"Prevention of Cardiovascular Disease With Polypill Among Pars Cohort Participants","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2015-12-20","conditions":"Cardiovascular Diseases","enrollment":4415},{"nctId":"NCT03541109","phase":"PHASE3","title":"A Polypill for Secondary Prevention of Ischemic Heart Disease","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2019-05-20","conditions":"Acute Myocardial Infarction, ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction","enrollment":1200},{"nctId":"NCT01245608","phase":"PHASE3","title":"Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-10","conditions":"Cardiovascular Diseases","enrollment":2400},{"nctId":"NCT01271985","phase":"PHASE3","title":"Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-02","conditions":"Cardiovascular Diseases","enrollment":8410},{"nctId":"NCT00567307","phase":"PHASE2","title":"Polypill For Prevention of Cardiovascular Disease","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2009-01","conditions":"Cardiovascular Disease","enrollment":216},{"nctId":"NCT00982189","phase":"NA","title":"Cardiovascular Prevention for Persons With HIV","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2009-09","conditions":"HIV Infection, Cardiovascular Disease Risk","enrollment":37},{"nctId":"NCT02791958","phase":"PHASE2","title":"Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy","status":"UNKNOWN","sponsor":"Ferrer Internacional S.A.","startDate":"2016-03","conditions":"Hypertension","enrollment":528},{"nctId":"NCT01321255","phase":"PHASE3","title":"Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2012-01","conditions":"Myocardial Infarction","enrollment":2118},{"nctId":"NCT01506505","phase":"NA","title":"The Evening Versus Morning Polypill Utilization Study","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2012-07","conditions":"Cardiovascular Disease, Cerebrovascular Disease, Peripheral Arterial Disease","enrollment":78},{"nctId":"NCT01362218","phase":"PHASE2","title":"Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol","status":"TERMINATED","sponsor":"Ferrer Internacional S.A.","startDate":"2010-10","conditions":"Elevated LDL Cholesterol","enrollment":107},{"nctId":"NCT01057537","phase":"PHASE3","title":"UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2010-06","conditions":"Cardiovascular Diseases","enrollment":2004},{"nctId":"NCT00603590","phase":"PHASE2","title":"Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2006-11","conditions":"Cardiovascular Disease, Hypertension, Hyperlipidemia","enrollment":475}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Polypill"],"phase":"phase_3","status":"active","brandName":"Cardiovascular Polypill","genericName":"Cardiovascular Polypill","companyName":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","companyId":"fundaci-n-centro-nacional-de-investigaciones-cardiovasculares-carlos-iii","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A fixed-dose combination pill that combines multiple cardiovascular agents to reduce the risk of heart disease and stroke through complementary mechanisms including blood pressure lowering, lipid reduction, and antiplatelet effects. Used for Cardiovascular disease prevention and secondary prevention in high-risk patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}